Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM which is resistant to key antitumor drugs, first generatio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aleksei Vladilenovich Petrov, D. V. Motorin, O. S. Pokrovskaya, E. S. Urnova, M. V. Nareiko, D. V. Babenetskaya, Yu. A. Alekseeva, L. L. Girshova, L. P. Mendeleeva, A. Yu. Zaritskii
Médium:	Artigo
Jazyk:	Russo
Vydáno:	Practical Medicine Publishing House 2017-07-01
Edice:	Клиническая онкогематология
Témata:	multiple myeloma “double-refractoriness” immunomodulating agents pomalidomide
On-line přístup:	https://bloodjournal.ru/index.php/coh/article/view/440
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!